Nektar Therapeutics (NKTR) Non-Current Assets (2010 - 2026)

Nektar Therapeutics' Non-Current Assets history runs 17 years deep, the most recent figure standing at $174.2 million for Q1 2026.

• In Q1 2026, Non-Current Assets rose 561.77% year-over-year to $174.2 million; the TTM figure through Mar 2026 stood at $229.3 million (up 65.56% YoY), while the FY2025 annual figure was $14.1 million, down 66.77% from the prior year.
• Non-Current Assets was $174.2 million for Q1 2026 at Nektar Therapeutics, up from $14.1 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $290.7 million in Q1 2022 to a low of $14.1 million in Q4 2025.
• Historically, Non-Current Assets has averaged $88.9 million across 5 years, with a median of $53.2 million in 2023.
• The sharpest annual moves came in 2023 and 2026: Non-Current Assets plunged 76.19% in 2023, then soared 561.77% in 2026.
• A 5-year view of Non-Current Assets shows it stood at $164.6 million in 2022, then plunged by 59.1% to $67.3 million in 2023, then tumbled by 36.79% to $42.6 million in 2024, then sank by 66.77% to $14.1 million in 2025, then jumped by 1132.18% to $174.2 million in 2026.
• The last three Non-Current Assets figures came in at $174.2 million (Q1 2026), $14.1 million (Q4 2025), and $20.0 million (Q3 2025), per Business Quant data.